Indane Derivatives as Selective HIF-2α Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with Hypoxia-Inducible Factor 2α (HIF-2α) lack specificity, often affecting both HIF-2α and HIF-1α, leading to unintended toxicity and limited therapeutic benefits, particularly in cancers and inflammatory disorders where targeted inhibition of HIF-2α is desired.
Innovation Solution
Development of specific indane compounds that act as HIF-2α inhibitors, formulated as pharmaceutical compositions, to treat diseases such as renal cancer, inflammatory bowel disease, and pulmonary arterial hypertension, with minimal impact on HIF-1α activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to inhibit HIF-2α, then therapeutic benefits are achieved, but HIF-1α is also affected leading to unintended toxicity
Solution Approach 1:
The patent segments the HIF inhibition function into two distinct pathways by developing compounds that selectively inhibit HIF-2α while sparing HIF-1α. This is achieved through specific molecular structure design (indane derivatives with particular substitution patterns) that confers selectivity for the HIF-2α binding pocket, thereby providing therapeutic benefits while avoiding the toxicity associated with pan-HIF inhibition.
Solution Approach 2:
The invention applies local quality by designing compounds with specific local structural features (substituents at positions 1, 2, and 6 of the indane core) that create selective interaction with HIF-2α. These localized structural modifications enable the compound to differentiate between HIF-1α and HIF-2α binding sites, achieving selective inhibition that reduces off-target toxicity while maintaining therapeutic efficacy.
2Adaptability or versatility
If non-specific HIF inhibitors are used, then broad hypoxia pathway inhibition is achieved, but disease-specific therapeutic outcomes are limited
Solution Approach 1:
The patent divides the broad HIF inhibition effect into selective HIF-2α inhibition, recognizing that different diseases require targeted approaches. By segmenting the inhibition specificity, the compounds can be optimized for particular disease indications (e.g., renal cell carcinoma, pulmonary arterial hypertension, inflammatory bowel disease) where HIF-2α plays a predominant role, thereby improving disease-specific therapeutic outcomes.
Solution Approach 2:
The invention changes the selectivity parameter of HIF inhibition by modifying the chemical structure of indane derivatives. Specific substitutions at defined positions on the indane core alter the compound's binding characteristics, shifting the selectivity profile from non-specific to HIF-2α-preferring, which enables better matching of therapeutic intervention to disease mechanism.
Data Source
AI summary
The present disclosure provides certain indane compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.